Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

NCT07063862 is registered in ClinicalTrials.gov with Bruyère Health Research Institute. as lead sponsor.

NCT NCT07063862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07063862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial
Lead sponsor
Bruyère Health Research Institute.
Phase
Phase 3
Overall status
Recruiting
Start date
January 28, 2026
Completion date
September 30, 2027
Enrollment
120 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

psychological distress